NCT02624063View on ClinicalTrials.gov

Randomized Clinical Trial of Sofosbuvir in Combination With Daclatasvir or Simeprevir for 12 Weeks in Non-cirrhotic Subjects Infected With Chronic Hepatitis C Virus Genotype 1 (TNT)

PHASE4CompletedINTERVENTIONAL
Enrollment

121

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

March 31, 2017

Study Completion Date

May 31, 2017

Conditions
Hepatitis C, Chronic
Interventions
DRUG

Daclatasvir + Sofosbuvir

Sofosbuvir 400 mg tablet + Daclatasvir 60 mg tablet oral dosing once daily for 12 weeks

DRUG

Simeprevir + Sofosbuvir

Sofosbuvir 400 mg tablet + Simeprevir 150 mg tablet oral dosing once daily for 12 weeks

Trial Locations (1)

04025-001

Outpatient Clinic of Viral Hepatitis (NUPAIG), São Paulo

All Listed Sponsors
lead

Federal University of São Paulo

OTHER

NCT02624063 - Randomized Clinical Trial of Sofosbuvir in Combination With Daclatasvir or Simeprevir for 12 Weeks in Non-cirrhotic Subjects Infected With Chronic Hepatitis C Virus Genotype 1 (TNT) | Biotech Hunter | Biotech Hunter